Investigational drug · Phase 2
LP-184
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Solid Tumor, Metastatic Solid Tumor, GBM.
Phase 2Last checked: Nov 19, 2026Latest source record: May 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "LP-184"
First trial start
2023
Jun 9, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LP-184", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumor
- Metastatic Solid Tumor
- GBM
- TNBC - Triple-Negative Breast Cancer
- NSCLC
- Pancreatic Adenocarcinoma
- DDR Gene Mutation
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "LP-184" as an intervention, largest first.
Starlight Therapeutics Inc.Industry
NCT07431216 · 68 participants (planned) · Start May 1, 2026 · Primary completion May 1, 2027
Drug: STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle.; Spironolactone (drug) · For: Glioblastoma (GBM)
- Study of LP-184 in Patients With Advanced Solid TumorsActive, not recruiting
Lantern Pharma Inc.Industry
NCT05933265 · 64 participants · Start Jun 9, 2023 · Primary completion Jul 28, 2026
Drug: LP-184; Olaparib and 1 more · For: Advanced Solid Tumor; Metastatic Solid Tumor; GBM and 4 more
Sites: Springdale, Arkansas; Indianapolis, Indiana; Louisville, Kentucky · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Phase Ia Evaluation of LP-184 in Recurrent Glioblastoma: Safety, Pharmacokinetics, and Translational Optimization of CNS Exposure.
Schreck KC, Lal B, Zhou J, et al. · Cancer Res Commun 2026
- A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors.
Mahadevan D, Parekh J, Beck JT, et al. · Invest New Drugs 2026
- Quantitative characterization of platelet count and alanine aminotransferase dynamics to inform personalized dosing in the first-in-human LP-184 trial.
Zhou J, Mahadevan D, Parekh J, et al. · Cancer Chemother Pharmacol 2026
- Chemotherapeutic induction of cytosolic single-stranded DNA accumulation sensitizes triple-negative breast cancer to immunotherapy.
Du Y, Yang L, Dai H, et al. · J Immunother Cancer 2026
- LP-184, a Novel Acylfulvene Molecule, Exhibits Anticancer Activity against Diverse Solid Tumors with Homologous Recombination Deficiency.
Kulkarni A, Zhou J, Biyani N, et al. · Cancer Res Commun 2024
- Preclinical Efficacy of LP-184, a Tumor Site Activated Synthetic Lethal Therapeutic, in Glioblastoma.
Lal B, Kulkarni A, McDermott J, et al. · Clin Cancer Res 2023
Also in development for Advanced Solid Tumor
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.